{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":8,"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03833167\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03833167","nct_id":"NCT03833167","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03833167. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-20","type":"ACTUAL"},"conditions":["Carcinoma, Squamous Cell"],"enrollment":{"count":450,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy","timeFrame":"Up to approximately 62 months"}],"references":[],"start_date":{"date":"2019-04-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)","url":"https://clinicaltrials.gov/study/NCT03833167"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03833167"}